Head and neck cancer: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• PD-1 70
• PD-L1 42
• TP53 7
• EGFR 33
• PI3K 6
• STAT3 1
• BRAF 0
• AKT 2
• mTOR 0
• HER2 6
• RET 0
• MAPK 0
• ERK 0
• STING 0
• PTEN 1
• TERT 0
• CTNNB1 0
• JAK 1
• CTLA-4 4
• NRF2 0
• MYC 0
• VEGF 4
• YAP 1
• HIF-1 0
• MET 3
• AMPK 0
• CLDN18 0
• IL-6 2
• JNK 0
• PARP 1
• FGFR 1
• GPX4 0
• B7-H3 5
• COX-2 0
• LAG-3 2
• TROP2 5
• EZH2 0
• MEK 0
• METTL3 0
• CD47 1
• PIK3CA 4
• CDK4/6 2
• NLRP3 0
• ATM 0
• PKM2 0
• TNF 0
• FAK 0
• MMP-9 0
• PPAR 0
• PSMA 1
• TLR4 0
• BCL-2 0
• HSP90 0
• KRAS 0
• NOTCH1 0
• NTRK 1
• ALK 0
• CD40 1
• CDKN2A 2
• CXCR4 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetic Profiling and Telomere-Orchestrated Mechanisms in HPV+ Oropharyngeal Cancer (EPiTOME-M)

  Royal College of Surgeons in Ireland· Dublin 2, Ireland· EU contribution €268,569· until Nov 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Endoscopic tissue time machine (EPIC)

  King's College London· London, United Kingdom· EU contribution €2,273,033· until May 2031

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  From Whisper to Voice: Real-Time on-Device Assistive AI Technology for Human Connection (Whispp)

  Whispp Bv· Leiden, Netherlands· EU contribution €2,498,319· until May 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  INHIBITING RESISTANCE TO IMMUNOTHERAPY IN HEAD&NECK CANCER BY TARGETING NETRIN-1 (NeckNET)

  Netris Pharma Sas· Lyon, France· EU contribution €7,248,398· until May 2030· 4 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  Early clinical development of first-in-class EGL-001 targeting Tregs in head and neck squamous cell carcinoma, supported by AI-based pathomics (NEOTREG)

  Egle Therapeutics· Suresnes, France· EU contribution €7,999,120· until Nov 2028· 4 countries

5 of 12 running projects, newest first. Listed amounts together: €36.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

  NCT03114319· Novartis Pharmaceuticals· Updated 9 Jul 2026

  “Business reasons and not due to any safety concerns”Registry text, quoted unchanged. Source

• Terminated

  Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

  NCT04000529· Novartis Pharmaceuticals· Updated 30 Sept 2025

  “Business reasons”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 84
• Organoids 23
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 13
• Gene Expression Profiling 244
• Sequence Analysis, RNA 26
• Whole Genome Sequencing 7
• Exome Sequencing 22
• Proteomics 65
• Metabolomics 43
• Mass Spectrometry 14
• Flow Cytometry 56
• Immunohistochemistry 333
• Liquid Biopsy 34
• Circulating Tumor DNA 57
• Xenograft Model Antitumor Assays 307
• Positron-Emission Tomography 83
• Magnetic Resonance Imaging 276
• Machine Learning 232
• Deep Learning 187
• Cohort Studies 296
• Genome-Wide Association Study 55

• Causal effects of antihypertensive drugs on thyroid diseases: A trans-ancestry drug-target Mendelian randomization study.

  Medicine (Baltimore), Oct 2026

• Causal association between fibroblast growth factors (FGFs) and gastric cancer: A two-sample Mendelian randomization study.

  Int J Biol Markers, Oct 2026

• Association Between Oral Cavity Cancer and Lymphoma: A Bidirectional Mendelian Randomization Analysis.

  Oral Health Prev Dent, Aug 2026

• Causal Association Between Antidepressant Use and Thyroid Disease Risk: A Two-Sample Mendelian Randomization Study.

  Actas Esp Psiquiatr, Aug 2026

• A Two-Sample Mendelian Randomisation Analysis of the Oral Microbiome and Oral/Oropharyngeal/Tongue Cancers.

  Oral Health Prev Dent, Aug 2026

• Multi-Omics Profiling Identifies Novel Therapeutic Targets and Pathobiological Mechanisms in Oral Cancer.

  J Cell Mol Med, Aug 2026

• Deciphering the Relationship Between Alcohol Consumption, Oropharyngeal Cancers, and Socioeconomic Determinants.

  Alcohol Clin Exp Res (Hoboken), Aug 2026

• Blood Manganese and Risk of Squamous Cell Carcinomas of the Head and Neck.

  JAMA Otolaryngol Head Neck Surg, Aug 2026

• Exploring the potential causal relationship between lipid metabolism and oral carcinoma in situ: A 2-sample Mendelian randomization study.

  Medicine (Baltimore), Jul 2026

• Genetically predicted vitamin D levels and risk of head and neck cancer: a mendelian randomization study.

  Cancer Causes Control, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.